Purdue Pharma L.P. Names Mark Timney President and Chief Executive Officer

Stamford, CT – January 23, 2014 – Purdue Pharma L.P. today announced that the company’s Board of Directors has appointed Mark Timney as President and Chief Executive Officer.

“We found a proven leader in Mark Timney,” said Dr. Raymond Sackler, co-founder and board member of Purdue. “I am confident that his capabilities and experience, coupled with Purdue’s culture of excellence, will grow our business and strengthen our healthcare industry leadership.”

Mark brings more than 20 years of pharmaceutical sales and marketing experience to Purdue, including success in designing and executing strategies to achieve market leadership. Prior to joining Purdue, he was President of Merck US, where he managed Sales & Marketing, Managed Markets, and Payers. With Mark’s guidance, Purdue will continue advancing breakthrough research and development initiatives and pioneering new commercial models.

“I’m honored to begin this new journey at Purdue Pharma, the industry leader in developing innovative medicines to relieve the burden of pain,” said Mark Timney. “I look forward to working with Purdue’s exceptional colleagues to achieve long-term success by broadening our pain management portfolio.”

During Mark’s tenure in the US market, he achieved a record of strong financial growth; launched several key products; led transformational business development; and played a key role in pipeline governance. Before coming to the United States, Mark served for seven years as Merck’s Country Manager in Korea and then Japan. Prior to that, he held leadership positions for more than four years at Merck Australia. Before joining Merck, he spent eight years in sales and marketing at a number of multinational pharmaceutical companies, including Zeneca in New Zealand, ICI Pharmaceuticals in Australia, and Roussel Labs in the United Kingdom.

Mark Timney succeeds John Stewart, who has retired from Purdue.

About Purdue Pharma L.P.

Purdue Pharma L.P. and its associated U.S. companies are privately-held pharmaceutical companies known for pioneering research on persistent pain. Headquartered in Stamford, CT, Purdue is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products. Additional information about Purdue can be found at www.purduepharma.com.

Contact:

Robert Josephson
Associate Director, Media Relations
(203) 588-7114
Email: robert.josephson@pharma.com

or

Jim Heins
Senior Director, Public Affairs
(203) 588-8069
Email: james.heins@pharma.com

The prescription and illicit opioid abuse crisis is a multifaceted public health challenge, and as a manufacturer of prescription opioids, we have a responsibility to join the fight. At Purdue we are committed to lead our industry in helping address our nation's prescription and illicit opioid abuse crisis.

There is more to come – as we continue to work with partners and experts to deliver solutions. Below you will find additional information about our efforts.

Read our open letter about the opioid crisis.